Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma Announces Senior Management Changes

Dr. David Zaccardelli appointed President and Chief Executive Officer Mark W. Hahn appointed Chief Financial Officer LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)...
January 28, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Present at LSX World Congress 2020

LONDON, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
January 17, 2020 08:06 ET | Source: Verona Pharma plc

Holding(s) in Company TR-1: Standard form for notification of major holdings

LONDON, Jan. 17, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word...
January 13, 2020 00:00 ET | Source: Verona Pharma plc

Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function Clinically relevant secondary endpoints met, including...
January 10, 2020 18:00 ET | Source: Verona Pharma plc

Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy

LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, will release...
January 07, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations

LONDON, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the...
November 28, 2019 05:24 ET | Source: Verona Pharma plc

Holding(s) in Company TR-1: Standard form for notification of major holdings

LONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word...
November 27, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc: Grant of Options to PDMR

LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that, on November 26,...
November 18, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc: PDMR Dealing – Purchase by Chairman

LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr....
November 14, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc: PDMR Dealing – Purchase by Chairman

LONDON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr....